Evolution of β-blockers: From anti-anginal drugs to ligand-directed signalling

Trends in Pharmacological Sciences

Volumn 32, Issue 4, 2011, Pages 227-234

  Baker, Jillian G ^a   Hill, Stephen J ^a   Summers, Roger J ^b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPRENOLOL; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CARTEOLOL; CARVEDILOL; CATECHOLAMINE; CELIPROLOL; CLENBUTEROL; DICHLORISOPRENALINE; ESMOLOL; ISOPRENALINE; LABETOLOL; LEVOBUNOLOL; METIPRANOLOL; METOPROLOL; NADOLOL; NEBIVOLOL; NORADRENALIN; OXPRENOLOL; PINDOLOL; PRACTOLOL; PRONETALOL; PROPRANOLOL; SALBUTAMOL; SOTALOL; TIMOLOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGINA PECTORIS; ANTIARRHYTHMIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANXIETY DISORDER; ASTHMA; DRUG INHIBITION; DYSPNEA; FRACTURE; GLAUCOMA; HEART ARRHYTHMIA; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; INVERSE AGONISM; ISCHEMIC HEART DISEASE; LUNG FUNCTION; MALARIA FALCIPARUM; MIGRAINE; MOLECULAR EVOLUTION; NONHUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PARTIAL AGONISM; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THYROTOXICOSIS; TREATMENT INDICATION;

ADRENERGIC BETA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANGINA PECTORIS; ANIMALS; ARRHYTHMIAS, CARDIAC; DRUG INVERSE AGONISM; HUMANS; LIGANDS; PHARMACOLOGY; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 79954449519     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2011.02.010     Document Type: Review

References (134)

1. J. Black A life in new drug research Br. J. Pharmacol. 160 Suppl. 1 2010 S15 S25
2. J.W. Black An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation Br. J. Pharmacol. 84 1985 561 571 (Pubitemid 15169246)
3. J. Lyall James Black: Nobel prize winning pharmacologist who invented β blockers Br. Med. J. 340 2010 c1817
4. R.P. Ahlquist A study of the adrenotropic receptors Am. J. Physiol. 153 1948 586 600
5. C.E. Powell, and I.H. Slater Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol J. Pharmacol. Exp. Ther. 122 1958 480 488
6. J.W. Black Comparison of some properties of pronethalol and propranolol Br. J. Pharmacol. Chemother 25 1965 577 591
7. J.W. Black, and B.N. Prichard Activation and blockade of β-adrenoceptors in common cardiac disorders Br. Med. Bull. 29 1973 163 167
8. B.N. Prichard Hypotensive action of pronethalol Br. Med. J. 1 1964 1227 1228
9. B.N. Prichard, and P.M. Gillam Use of propranolol (Inderal) in treatment of hypertension Br. Med. J. 2 1964 725 727
10. B.N. Prichard The second Lilly Prize Lecture, University of Newcastle, July 1977. (β-Adrenergic receptor blockade in hypertension, past, present and future Br. J. Clin. Pharmacol. 5 1978 379 399 (Pubitemid 8325681)
11. -(1986) Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 2, 57-66.
12. -(1982) A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. J Am Med Assoc 247, 1707-1714.
13. H.J. Dargie Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial Lancet 357 2001 1385 1390 (Pubitemid 32455364)
14. A. Hjalmarson Effect on mortality of metoprolol in acute myocardial infarction A double-blind randomised trial Lancet 2 1981 823 827 (Pubitemid 11017550)
15. T.R. Pedersen Six-year follow-up of the Norwegian Multicenter Study on Timolol after Acute Myocardial Infarction N. Engl. J. Med. 313 1985 1055 1058 (Pubitemid 16243333)
16. H.R. Black The foundation role of β-blockers across the cardiovascular disease spectrum: a year 2009 update Am. J. Med. 123 2010 S2
17. C.H. Selzman The case for β-adrenergic blockade as prophylaxis against perioperative cardiovascular morbidity and mortality Arch. Surg. 136 2001 286 290 (Pubitemid 32204964)
18. N. Echahidi Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery J. Am. Coll. Cardiol. 51 2008 793 801 (Pubitemid 351255619)
19. E. Shantsila Atrial fibrillation post-cardiac surgery: changing perspectives Curr. Med. Res. Opin. 22 2006 1437 1441 (Pubitemid 44297422)
20. E. Crystal Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery Cochrane Database Syst. Rev. 2004 CD003611
21. A.D. Auerbach, and L. Goldman β-Blockers and reduction of cardiac events in noncardiac surgery: scientific review J. Am. Med. Assoc. 287 2002 1435 1444 (Pubitemid 34250507)
22. N.K. Hollenberg The role of β-blockers as a cornerstone of cardiovascular therapy Am. J. Hypertens. 18 2005 165S 168S (Pubitemid 41803604)
23. W.S. Aronow Current role of β-blockers in the treatment of hypertension Expert Opin. Pharmacother. 11 2010 2599 2607
24. S. Bangalore Cardiovascular protection using β-blockers: a critical review of the evidence J. Am. Coll. Cardiol. 50 2007 563 572 (Pubitemid 47202065)
25. J.N. Basile One size does not fit all: the role of vasodilating β-blockers in controlling hypertension as a means of reducing cardiovascular and stroke risk Am. J. Med. 123 2010 S9 15
26. i coupling Naunyn. Schmiedebergs Arch. Pharmacol. 375 2007 11 28 (Pubitemid 46354559)
27. 1-receptor down-regulation in heart failure Circ. Res. 59 1986 297 309 (Pubitemid 17178124)
28. B.F. Buxton Characterization and autoradiographic localization of β-adrenoceptor subtypes in human cardiac tissues Br. J. Pharmacol. 92 1987 299 310
29. 3-adrenoceptors in the human heart? Br. J. Pharmacol. 162 2011 817 822
30. S. Lee Genetically changed mice with chronic deficiency or overexpression of the β-adrenoceptors - what can we learn for the therapy of heart failure? Pflugers Arch. 455 2008 767 774 (Pubitemid 350265613)
31. D.J. van Veldhuisen, and P.A. Poole-Wilson The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure Int. J. Cardiol. 80 2001 19 27 (Pubitemid 32800800)
32. F. Waagstein Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy Br. Heart J. 37 1975 1022 1036
33. K. Swedberg Prolongation of survival in congestive cardiomyopathy by β-receptor blockade Lancet 1 1979 1374 1376 (Pubitemid 9204152)
34. -(1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13.
35. -(1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007.
36. M. Packer Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study Circulation 106 2002 2194 2199 (Pubitemid 35222212)
37. M.D. Flather Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur. Heart J. 26 2005 215 225 (Pubitemid 40222359)
38. K.E. Ellison, and G. Gandhi Optimising the use of β-adrenoceptor antagonists in coronary artery disease Drugs 65 2005 787 797 (Pubitemid 40593627)
39. J.M. Cruickshank Are we misunderstanding β-blockers Int. J. Cardiol. 120 2007 10 27
40. The Beta-Blocker Evaluation of Survival Trial Investigators (2001) A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 344, 1659-1667.
41. The Xamoterol in Severe Heart Failure Study Group (1990) Xamoterol in severe heart failure. Lancet 336, 1-6.
42. C. Maack Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium Br. J. Pharmacol. 130 2000 1131 1139 (Pubitemid 30453549)
43. P. Andreka Bucindolol displays intrinsic sympathomimetic activity in human myocardium Circulation 105 2002 2429 2434 (Pubitemid 34556397)
44. R.L. Stamper Primary drug treatment for glaucoma: β-blockers versus other medications Surv. Ophthalmol. 47 2002 63 73
45. V. Limmroth, and M.C. Michel The prevention of migraine: a critical review with special emphasis on β-adrenoceptor blockers Br. J. Clin. Pharmacol. 52 2001 237 243 (Pubitemid 33796220)
46. R.N. Gray Drug Treatments for the Prevention of Migraine Headache 1999 Agency for Health Care Policy and Research (US)
47. P. Turner Therapeutic uses of β-adrenoceptor blocking drugs in the central nervous system in man Postgrad. Med. J. 65 1989 1 6 (Pubitemid 19051802)
48. G. Mehta Developments and controversies in the management of oesophageal and gastric varices Gut 59 2010 701 705
49. R.J. Uitti Medical treatment of essential tremor and Parkinson's disease. Geriatrics 53 1998 47 53
50. J. Feely, and N. Peden Use of β-adrenoceptor blocking drugs in hyperthyroidism Drugs 27 1984 425 446 (Pubitemid 14130528)
51. J.A. Pasco β-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study J. Bone Miner. Res. 19 2004 19 24 (Pubitemid 41295133)
52. R.G. Schlienger Use of β-blockers and risk of fractures J. Am. Med. Assoc. 292 2004 1326 1332
53. L. Rejnmark Treatment with β-blockers ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study J. Hypertens. 24 2006 581 589 (Pubitemid 43261923)
54. M. Schoo Use of β-blockers is associated with BMD and fracture risk Bone 36 2005 129 130
55. N. Bonnet Protective effect of β-blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture Bone 40 2007 1209 1216 (Pubitemid 46553796)
56. S. Yang Association between β-blocker use and fracture risk: The Dubbo Osteoporosis Epidemiology Study Bone 48 2011 451 455
57. F. de Vries Use of β-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands Calcif. Tissue Int. 80 2007 69 75 (Pubitemid 46294972)
58. R. Lavasseur β-Blocker use, bone mineral density and fracture risk in older women: results from the Epidemiologie de L'Osteoporose Prospective Study J. Am. Geriatr. Soc. 53 2005 550 552
59. I.R. Reid β-Blocker use, BMD, and fractures in the study of osteoporotic fractures J. Bone Miner. Res. 20 2005 613 618 (Pubitemid 40393069)
60. C. Meisinger β-Blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study Osteoporos. Int. 18 2007 1189 1195 (Pubitemid 47300270)
61. B. Minkowitz Effects of propranolol on bone metabolism in the rat J. Orthop. Res. 9 1991 869 875
62. S. Takeda Leptin regulates bone formation via the sympathetic nervous system Cell 111 2002 305 317 (Pubitemid 35345151)
63. 2-agonists treatment Med. Sci. Sports Exerc. 37 2005 1493 1501 (Pubitemid 41368492)
64. F. Elefteriou Regulation of bone remodeling by the central and peripheral nervous system Arch. Biochem. Biophys. 473 2008 231 236
65. 2- adrenergic receptors in human osteoblasts J. Cell. Physiol. 220 2009 267 275
66. N. Bonnet Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis J. Musculoskelet Neuronal Interact. 8 2008 94 104
67. M. Algazi [Could treatments with β-blockers be associated with a reduction in cancer risk?] Rev. Epidemiol. Sante Publique 52 2004 53 65 (Pubitemid 38468653)
68. L. Perron Antihypertensive drug use and the risk of prostate cancer (Canada) Cancer Causes Cont. 15 2004 535 541 (Pubitemid 39070071)
69. E.K. Sloan The sympathetic nervous system induces a metastatic switch in primary breast cancer Cancer Res. 70 2010 7042 7052
70. A.K. Sood Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis J. Clin. Invest. 120 2010 1515 1523
71. S. Rajagopal Teaching old receptors new tricks: biasing seven-transmembrane receptors Nat. Rev. Drug Discov. 9 2010 373 386
72. T. Harrison Erythrocyte G protein-coupled receptor signaling in malarial infection Science 301 2003 1734 1736 (Pubitemid 37174369)
73. S.C. Murphy Erythrocyte G protein as a novel target for malarial chemotherapy PLoS Med. 3 2006 e528
74. P.B. Decalmer β-Blockers, asthma Br. Heart J. 40 1978 184 189
75. J.H. van den Bergh, and C.L. van Herwaarden Ventilatory effects of ordinary and slow-release tablets of metoprolol in asthmatic patients Eur. J. Respir. Dis. 62 1981 168 172 (Pubitemid 11040333)
76. 1-selective blocking agents in asthmatic patients Eur. J. Clin. Pharmacol. 20 1981 417 421 (Pubitemid 11004024)
77. C.G. Lofdahl, and N. Svedmyr Cardioselectivity of atenolol and metoprolol A study in asthmatic patients Eur. J. Respir. Dis. 62 1981 396 404 (Pubitemid 12203843)
78. H.W. Clague Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to β-blockade Eur. J. Clin. Pharmacol. 27 1984 517 523 (Pubitemid 15176755)
79. C.G. Lofdahl, and N. Svedmyr Effects of xamoterol (ICI 118,587) in asthmatic patients Br. J. Clin. Pharmacol. 18 1984 597 601 (Pubitemid 14009955)
80. J.W. Lammers Respiratory tolerance of bisoprolol and metoprolol in asthmatic patients J. Cardiovasc. Pharmacol. 8 Suppl. 11 1986 S69 S73
81. J.W. Lammers A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients Br. J. Clin. Pharmacol. 22 1986 595 602 (Pubitemid 17177038)
82. 1-selective blocking agents atenolol and bevantolol in asthmatic patients Eur. J. Clin. Pharmacol. 30 1986 13 16 (Pubitemid 16166976)
83. A. Miki Betaxolol-induced deterioration of asthma and a pharmacodynamic analysis based on β-receptor occupancy Int. J. Clin. Pharmacol. Ther. 41 2003 358 364 (Pubitemid 36975196)
84. M.K. Benson A comparison of four β-adrenoceptor antagonists in patients with asthma Br. J. Clin. Pharmacol. 5 1978 415 419 (Pubitemid 8325684)
85. E. Kotlyar Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma J. Heart Lung Transplant. 21 2002 1290 1295 (Pubitemid 35477743)
86. G. Devereux Adverse effects of a single dose of (+)-sotalol in patients with mild stable asthma Br. J. Clin. Pharmacol. 46 1998 79 82 (Pubitemid 28308428)
87. C.C. Chafin β-Blockers after myocardial infarction: do benefits ever outweigh risks in asthma? Cardiology 92 1999 99 105 (Pubitemid 30135938)
88. N.A. Hanania The safety and effects of the β-blocker, nadolol, in mild asthma: an open-label pilot study Pulm. Pharmacol. Ther. 21 2008 134 141
89. R.A. Bond Getting to the heart of asthma: can 'β blockers' be useful to treat asthma? Pharmacol. Ther. 115 2007 360 374 (Pubitemid 47364804)
90. J.G. Baker The selectivity of β-adrenoceptor antagonists at the human β1 β2 and β3 adrenoceptors Br. J. Pharmacol. 144 2005 317 322 (Pubitemid 40313677)
91. C. Hoffmann Comparative pharmacology of human β-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells Naunyn. Schmiedebergs Arch. Pharmacol. 369 2004 151 159 (Pubitemid 38270770)
92. 3- Adrenoceptor 2000 Taylor & Francis 48-76
93. C. Smith, and M. Teitler β-Blocker selectivity at cloned human β1- and β2-adrenergic receptors Cardiovasc. Drugs Ther. 13 1999 123 126 (Pubitemid 29224837)
94. P. Schnabel Binding properties of β-blockers at recombinant β1-β2-, and β3-adrenoceptors. J. Cardiovasc. Pharmacol. 36 2000 466 471
95. J.G. Baker The selectivity of β-adrenoceptor agonists at human β1-β2- and β3-adrenoceptors. Br. J. Pharmacol. 160 2010 1048 1061
96. 3-adrenoceptors - findings and challenges Naunyn. Schmiedebergs Arch. Pharmacol. 382 2010 103 108
97. J.R. Jasper Amplification of cyclic AMP generation reveals agonistic effects of certain β-adrenergic antagonists Mol. Pharmacol. 37 1990 44 49 (Pubitemid 20038448)
98. J.R. Jasper Molecular mechanism of β-adrenergic receptor blockers with intrinsic sympathomimetic activity FASEB J. 2 1988 2891 2894
99. 1-adrenoceptor in human atrium and recombinant receptors Naunyn. Schmiedebergs Arch. Pharmacol. 368 2003 496 503 (Pubitemid 38041313)
100. J.G. Baker Agonist actions of 'β-blockers' provide evidence for two agonist activation sites or conformations of the human β1-adrenoceptor Mol. Pharmacol. 63 2003 1312 1321 (Pubitemid 36627226)
101. J.G. Baker Sites of action of β-ligands at the human β1-adrenoceptor J. Pharmacol. Exp. Ther. 313 2005 1163 1171 (Pubitemid 40727019)
102. 1-adrenoceptors in human myocardium J. Pharmacol. Exp. Ther. 300 2002 794 801 (Pubitemid 34164981)
103. 1-adrenergic receptor Am. J. Physiol. Endocrinol. Metab. 280 2001 E199 202
104. P. Molenaar The 'state' of β-adrenoceptors Br. J. Pharmacol. 140 2003 1 2
105. A.J. Kaumann Is there a third heart β-adrenoceptor? Trends Pharmacol. Sci. 10 1989 316 320
106. 3-adrenoceptor Mol. Pharmacol. 68 2005 1645 1655 (Pubitemid 41654348)
107. 3 and atypical β-adrenoceptors Med. Res. Rev. 13 1993 663 729
108. A.J. Kaumann [Cardiac β-receptors - experimental aspects] Z. Kardiol. 72 1983 63 82
109. M.D. Pak, and P.H. Fishman Anomalous behavior of CGP 12177A on (1-adrenergic receptors J. Recept. Signal Transduct. Res. 16 1996 1 23 (Pubitemid 26171456)
110. M. Walter Stimulant and blocking effects of optical isomers of pindolol on the sinoatrial node and trachea of guinea pig Role of β-adrenoceptor subtypes in the dissociation between blockade and stimulation. Naunyn. Schmiedebergs Arch. Pharmacol. 327 1984 159 175 (Pubitemid 14066545)
111. A.J. Kaumann, and J.R. Blinks β-Adrenoceptor blocking agents as partial agonists in isolated heart muscle: dissociation of stimulation and blockade Naunyn. Schmiedebergs Arch. Pharmacol. 311 1980 237 248 (Pubitemid 10096810)
112. 1-adrenergic receptors J. Pharmacol. Exp. Ther. 294 2000 923 932 (Pubitemid 30666842)
113. 4-adrenoceptor pharmacology Br. J. Pharmacol. 141 2004 813 824 (Pubitemid 38446182)
114. 2+ transients in mouse ventricular myocytes Naunyn. Schmiedebergs Arch. Pharmacol. 360 1999 445 456 (Pubitemid 29502993)
115. 1-adrenoceptor and its relevance to cardiovascular pharmacology Pharmacol. Ther. 118 2008 303 336
116. 3-receptor knockout mice Receptors Channels 7 2000 17 23 (Pubitemid 30224012)
117. 4-adrenoceptor pharmacology Naunyn. Schmiedebergs Arch. Pharmacol. 363 2001 87 93 (Pubitemid 32060091)
118. A.J. Kaumann, and P. Molenaar Modulation of human cardiac function through 4 β-adrenoceptor populations Naunyn. Schmiedebergs Arch. Pharmacol. 355 1997 667 681 (Pubitemid 27395692)
119. P. Chidiac Inverse agonist activity of β-adrenergic antagonists Mol. Pharmacol. 45 1994 490 499 (Pubitemid 24094939)
120. M. Azzi β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors Proc. Natl. Acad. Sci. U.S.A. 100 2003 11406 11411 (Pubitemid 37205948)
121. 2-adrenoceptor provide evidence for agonist-directed signaling Mol. Pharmacol. 64 2003 1357 1369 (Pubitemid 37532226)
122. 2-adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists J. Biol. Chem. 280 2005 22165 22171 (Pubitemid 40827872)
123. B.A. Evans Ligand-directed signalling at β-adrenoceptors Br. J. Pharmacol. 159 2011 1022 1038
124. T. Kenakin Functional selectivity and biased receptor signaling J. Pharmacol. Exp. Ther. 336 2010 296 302
125. J.W. Wisler A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling Proc. Natl. Acad. Sci. U.S.A. 104 2007 16657 16662 (Pubitemid 350211072)
126. 2-adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy Mol. Pharmacol. 70 2006 1575 1584
127. 3-adrenoceptor produced by 3-(2-ethylphenoxy)-1-[(1S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2- propanol oxalate (SR 59230A) relative to receptor agonists Mol. Pharmacol. 72 2007 1359 1368 (Pubitemid 350012609)
128. 3- adrenoceptor Mol. Pharmacol. 74 2008 1417 1428
129. 1- adrenergic receptor Mol. Pharmacol. 74 2008 162 172 (Pubitemid 351872167)
130. I.M. Kim β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation Proc. Natl. Acad. Sci. U.S.A. 105 2008 14555 14560
131. 3-adrenoceptor Naunyn. Schmiedebergs Arch. Pharmacol. 373 2006 158 168 (Pubitemid 43742441)
132. J.W. Black, and P. Leff Operational models of pharmacological agonism Proc. R. Soc. Lond. B: Biol. Sci. 220 1983 141 162 (Pubitemid 14217337)
133. T. Kenakin, and L.J. Miller Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 62 2010 265 304
134. 1A-adrenoceptor Mol. Pharmacol. 79 2010 298 307